Followers | 88 |
Posts | 8196 |
Boards Moderated | 0 |
Alias Born | 06/17/2013 |
Monday, June 20, 2022 12:37:58 PM
then follow the science, and enter the library :
https://forum.therapeuticsolutionsint.com/viewtopic.php?t=219
I'm talkin 'bout the waay beyond the front burner DD below on this list :
USPTO, FDA, SEC verified company
61+ patents and patent applications
5 Investigational Drug Applications
Phase 1/2 Solid Tumor Cancer
Phase 1/2 CTE
Phase 1/2 Breast Cancer
Phase 1/2 COPD
Phase 3 Lung Failure
Retail sold online @ Amazon & Walmart
If you really know your DD ,
then cross the R and D river with your MSCs from JadiCell , and venture into Transcranial Magnetic Stimulation, as well as Bio electric stimulation .
Campbell NeuroSciences ,
And Howard Leonhardt.
Therapeutic Solutions International Launches Campbell Neurosciences Division aimed at Biologically Identifying and Repairing Suicide-Prone Brains
Company Leverages Existing Immunology and Regenerative Medicine Intellectual Property to Attack Second Leading Cause of Death in Young People
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-launches-campbell-neurosciences-division-aimed-at-biologically-identifying-and-repairing-suicide-prone-brains-301110221.html
OCEANSIDE, Calif., Aug. 11, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today formation of Campbell Neurosciences, a new division of the Company dedicated to approaching suicide as a biological disorder and developing science-based diagnostic tools and interventions.
The Division will be headed by Kalina O'Connor, and is named after her mother, Kathleen Campbell, who was a victim of suicide. Ms. O'Connor has previously worked in the area of drug and alcohol rehabilitation, as well as assisting the Company in its basic research and development.
Howard Leonhardt, a serial inventor and entrepreneur, whose inventions have treated over 500,000 patients in 60 countries will serve as Advisor to the Division. Additionally, Dr. Erin Ferma, a forensic psychologist with over 15 years clinical experience will provide input on clinical trial design and practical implementation of the technologies under development. Former Congressional Candidate and Director of Business Development, Famela Ramos, will oversee operations.
"I am honored to be working with Timothy Dixon, a modern-day renaissance man, and the team at Therapeutic Solutions International. This organization has developed products and conducted successful preclinical and clinical trials on approaches which can modulate biological pathways linked to suicide" said Ms. O'Connor. "By leveraging existing findings and developing new intellectual property, we believe we are in the position to offer for the first time a suicide risk score which is based on science and not psychological self-assessment. Combined with identifying risk, we seek to develop various therapeutic approaches."
Previous studies have shown correlations between inflammatory cytokines in the blood and suicide. The causative effects of these molecules on suicidal ideation is seen in cancer patients who take similar molecules for hyperstimulation of immunity, which also results in suicidal ideation. Products developed by Therapeutic Solutions International such as NeuroStilbene™, NanoStilbene™ and QuadraMune™ have been shown to reduce inflammatory markers.
"It is extremely exciting to be at the ground floor of a paradigm shift" said Howard Leonhardt. "I look forward to assisting the Company in accelerating solutions for this terrible condition. "Additionally, we will explore synergistic interaction with various companies from the Leonhardt Ventures portfolio."
"Suicide has historically been treated as a stigma. With increasing advancement of science, we realize it is a biological abnormality and should be addressed the same way we address other conditions" said Timothy Dixon, President and CEO of the Company. "Psychiatry is the only discipline of medicine that does not base its drug prescriptions by detailed evaluation of the organ they are treating. It is interesting that only in psychiatry that treatments are given without actually assessing physical changes that the intervention is accomplishing. Technologies we are developing will provide a biological basis for the practice of psychiatry as it relates to suicide prevention."
Recent TSOI News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:29:10 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM